Tags

Type your tag names separated by a space and hit enter

Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response.
Transplant Proc. 2010 Jun; 42(5):1595-7.TP

Abstract

BACKGROUND

Ischemia-reperfusion (I/R) injury may influence graft function after transplantation. Erythropoietin (EPO) attenuates I/R injury in various animal organs such as intestine, brain, and kidney.

OBJECTIVE

To evaluate the effects of pretreatment with recombinant human EPO (rhEPO) on I/R-induced heart injury.

MATERIALS AND METHODS

A rat model of I/R injury was established by ligating the left descending coronary artery for 30 minutes, followed by reperfusion for 4 hours. Fifty Sprague-Dawley rats were divided into 5 groups: sham operation; I/R; I/R+rhEPO, 100 U/kg; I/R+rhEPO, 1000 U/kg; and I/R+rhEPO, 5000 U/kg. Electrocardiograms were assessed continuously to note arrhythmia caused by reperfusion. Serum concentrations of interleukin (IL)-6 and IL-8, and tumor necrosis factor-alpha were measured at 2 and 4 hours after reperfusion.

RESULTS

The rhEPO-treated animals exhibited dosage-dependent significant reduction in the incidence of ventricular arrhythmia caused by reperfusion, and markedly decreased serum concentrations of IL-6, IL-8, and tumor necrosis factor-alpha (P < .05) compared with the I/R group (P < .05).

CONCLUSION

The rhEPO attenuates myocardial I/R injury in rats, at least in part related to inhibition of the system inflammatory response.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Shen Y
Department of Cardio-thoracic Surgery, Jinling Hospital, Clinical Medicine School, Nanjing University, Nanjing, China.
Wang Y
No affiliation info available
Li D
No affiliation info available
Wang C
No affiliation info available
Xu B
No affiliation info available
Dong G
No affiliation info available
Huang H
No affiliation info available
Jing H
No affiliation info available

MeSH

AnimalsErythropoietinHumansInflammationInterleukin-6Interleukin-8Myocardial IschemiaMyocardial Reperfusion InjuryRatsRats, Sprague-DawleyRecombinant ProteinsReperfusion InjuryTumor Necrosis Factor-alpha

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20620481

Citation

Shen, Y, et al. "Recombinant Human Erythropoietin Pretreatment Attenuates Heart Ischemia-reperfusion Injury in Rats By Suppressing the Systemic Inflammatory Response." Transplantation Proceedings, vol. 42, no. 5, 2010, pp. 1595-7.
Shen Y, Wang Y, Li D, et al. Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Transplant Proc. 2010;42(5):1595-7.
Shen, Y., Wang, Y., Li, D., Wang, C., Xu, B., Dong, G., Huang, H., & Jing, H. (2010). Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Transplantation Proceedings, 42(5), 1595-7. https://doi.org/10.1016/j.transproceed.2009.11.050
Shen Y, et al. Recombinant Human Erythropoietin Pretreatment Attenuates Heart Ischemia-reperfusion Injury in Rats By Suppressing the Systemic Inflammatory Response. Transplant Proc. 2010;42(5):1595-7. PubMed PMID: 20620481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. AU - Shen,Y, AU - Wang,Y, AU - Li,D, AU - Wang,C, AU - Xu,B, AU - Dong,G, AU - Huang,H, AU - Jing,H, PY - 2009/09/16/received PY - 2009/11/24/accepted PY - 2010/7/13/entrez PY - 2010/7/14/pubmed PY - 2010/10/30/medline SP - 1595 EP - 7 JF - Transplantation proceedings JO - Transplant Proc VL - 42 IS - 5 N2 - BACKGROUND: Ischemia-reperfusion (I/R) injury may influence graft function after transplantation. Erythropoietin (EPO) attenuates I/R injury in various animal organs such as intestine, brain, and kidney. OBJECTIVE: To evaluate the effects of pretreatment with recombinant human EPO (rhEPO) on I/R-induced heart injury. MATERIALS AND METHODS: A rat model of I/R injury was established by ligating the left descending coronary artery for 30 minutes, followed by reperfusion for 4 hours. Fifty Sprague-Dawley rats were divided into 5 groups: sham operation; I/R; I/R+rhEPO, 100 U/kg; I/R+rhEPO, 1000 U/kg; and I/R+rhEPO, 5000 U/kg. Electrocardiograms were assessed continuously to note arrhythmia caused by reperfusion. Serum concentrations of interleukin (IL)-6 and IL-8, and tumor necrosis factor-alpha were measured at 2 and 4 hours after reperfusion. RESULTS: The rhEPO-treated animals exhibited dosage-dependent significant reduction in the incidence of ventricular arrhythmia caused by reperfusion, and markedly decreased serum concentrations of IL-6, IL-8, and tumor necrosis factor-alpha (P < .05) compared with the I/R group (P < .05). CONCLUSION: The rhEPO attenuates myocardial I/R injury in rats, at least in part related to inhibition of the system inflammatory response. SN - 1873-2623 UR - https://www.unboundmedicine.com/medline/citation/20620481/Recombinant_human_erythropoietin_pretreatment_attenuates_heart_ischemia_reperfusion_injury_in_rats_by_suppressing_the_systemic_inflammatory_response_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(10)00579-8 DB - PRIME DP - Unbound Medicine ER -